NCT01417936 - Sym004 in SCCHN Patients Failing Anti-EGFR Based Therapy | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 31, 2011

Primary Completion Date

October 31, 2012

Study Completion Date

October 31, 2012

Conditions

Carcinoma, Squamous Cell of Head and Neck

Interventions

DRUG

Sym004

Sym004 will be administered at the dose of 12 milligram per kilogram (mg/kg) as an intravenous infusion every week up to disease progression or withdrawal from treatment.

Trial Locations (10)

1000

3202; Jules Bordet Institute; Clinique d'Oncologie Médicale, Brussels

1200

3201; Cliniques Universitaires St-Luc; Centre du Cancer, Brussels

2650

3203; Antwerp University Hospital; Department of Medical Oncology, Antwerp

6912

4907; University Hospital Heidelberg; Nationales Centrum für Tumorerkrankungen (NCT), Heidelberg

12200

4905; Charité Campus Benjamin Franklin; Hematology, Oncology and Transfusion Medicine, Berlin

20246

4906; University Medical Center Hamburg Eppendorf; Department of Otorhinolaryngology and Head and Neck Surgery, Hamburg

45122

4901; Universitätsklinikum Essen, Essen

54111

3303; Centre Alexis Vautrin; Département d'Oncologie Médicale, Nancy

79106

4904; Universitätsklinikum Freiburg, Freiburg im Breisgau

04103

4902; University of Leipzig, Leipzig

All Listed Sponsors

lead

Symphogen A/S

INDUSTRY